FOR IMMEDIATE RELEASE
WEBSITE LAUNCHED FOR NOVEL EARLY CAD DIAGNOSTIC SYSTEM
El Monte, CA - February 27, 2009 - Bionetek Corporation launched a new website for its revolutionary Early Cardiac Diagnostic System: CARDx ECD. Unlike the older EKG, which is only 50% accurate, this quick, non-invasive novel technology boasts unprecedented detection rates of up to 94%.
Bionetek created this data-saturated website in response to the huge demand for information on CARDx ECD. This patented system incorporates 12-lead Crebro Cardiography technology, which has been previously utilized in FDA cleared products. Physicians are particularly interested in CARDx ECD, because of its extraordinary sensitivity in revealing the early stages of Coronary Artery Disease (CAD), including the normally elusive silent ischemia. Since early detection means early intervention, CARDx ECD promises to be useful in reducing the onset of a first myocardial infarction.
This resource-rich website contains:
- Clinical abstracts of research conducted in Ohio and New York hospitals
- Case studies detailed in an updated handbook
- Comprehensive comparison of CAD detection technologies summarized in a single table
To learn more about this novel method of detecting early stages of CAD, visit www.bionetek.com.
ABOUT BIONETEK
Bionetek Corporation revolutionizes cardiac diagnostics by commercializing proprietary novel technology that prevents, diagnose, differentiates, and tracks heart dysfunctions. Located in a 72,000 square foot, state-of-the-art manufacturing and development facility in Southern California, Bionetek leads the industry in non-invasive, stress-free, cardiac diagnostic technology.
Bionetek develops, manufactures, and markets the Early Cardiac Diagnostic System (CARDx ECD), whose technology is based on FDA-cleared instrumentation. Utilizing an advanced mathematical model, the CARDx ECD displays an unprecedented sensitivity in revealing and localizing heart abnormalities. For example, in a painless 10-minute test, the CARDx ECD detects CAD with an astounding 94% accuracy.
The CARDx ECD will have a profound impact on the early detection of heart diseases, which are responsible for over 800,000 annual deaths in the United States and over 7 million worldwide.
Contact:
Jiali Lu
(626) 456-8080
jialil@bionetek.com
www.bionetek.com